Literature DB >> 11543987

Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients.

M Backmund1, K Meyer, D Eichenlaub, C G Schütz.   

Abstract

Up to 1999 more opioid dependent patients in Germany were substituted with codeine or dihydrocodeine (summarised as codeine) than with methadone. The current retrospective study compares the differences in detoxification treatment outcome for codeine-substituted patients, methadone-substituted patients and patients injecting illicit heroin. The study is based on the medical records of 1070 patients admitted consecutively for opioid and polytox detoxification between 1991 and 1997. The main hypothesis was that injecting illicit-heroin users would complete detoxification treatment less often than codeine- or methadone- substituted patients, and that methadone-substituted patients who had received more structured treatment would complete more often than codeine-substituted patients who did not receive any structured treatment beyond the prescription of codeine. We analysed a number of demographic and drug related variables as possible predictors. Our bivariate analyses confirmed our main hypothesis: 50.4% (OR: 1.8) of the methadone-substituted patients, 45.5% (OR: 1.5) of the codeine-substituted patients and 35.9% (OR: 1 comparison group) of the injecting illicit-heroin users completed the detoxification program (P=0.006). This finding remained significant even after correcting for a number of confounders. Using stepwise multiple logistic regression analyses, we found age, education, history of imprisonment, regular contact with a counsellor, currently being on probation and reported plans for participating in an abstinence treatment program to be significant predictors of completing detoxification treatment. Although the current analysis did not rule out differences in pharmacological effects as a contributing factor, the results are consistent with an interpretation of a dose-response association between psychosocial/psychotherapeutic support and detoxification outcome. More psychosocial/psychotherapeutic support leads to better detoxification treatment response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11543987     DOI: 10.1016/s0376-8716(01)00122-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  14 in total

1.  Addiction treatment-related employment barriers: the impact of methadone maintenance.

Authors:  Lindsey Richardson; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Authors:  Douglas M Ziedonis; Leslie Amass; Marc Steinberg; George Woody; Jonathan Krejci; Jeffrey J Annon; Allan J Cohen; Nancy Waite-O'Brien; Susan M Stine; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Robert Maslansky; Theresa Winhusen; Dean Babcock; Greg Brigham; Joan Muir; Deborah Orr; Betty J Buchan; Terry Horton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-09-20       Impact factor: 4.492

3.  Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs.

Authors:  April Joy Damian; Tamar Mendelson; Deborah Agus
Journal:  Addict Behav       Date:  2017-05-10       Impact factor: 3.913

4.  Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997-2007.

Authors:  Giuliano Zamparutti; Fabrizio Schifano; John M Corkery; Adenekan Oyefeso; A Hamid Ghodse
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

5.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

6.  Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.

Authors:  Julia R Benville; Peggy Compton; Nicholas A Giordano; Martin D Cheatle
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

7.  A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification.

Authors:  Ekkehard Madlung-Kratzer; Bernhard Spitzer; Berhard Spitzer; Renate Brosch; Dirk Dunkel; Christian Haring
Journal:  Addiction       Date:  2009-09       Impact factor: 6.526

8.  Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.

Authors:  Tara Carney; Marie Claire Van Hout; Ian Norman; Siphokazi Dada; Nandi Siegfried; Charles Dh Parry
Journal:  Cochrane Database Syst Rev       Date:  2020-02-18

9.  Factors associated with pretreatment and treatment dropouts: comparisons between Aboriginal and non-Aboriginal clients admitted to medical withdrawal management.

Authors:  Xin Li; Huiying Sun; David C Marsh; Aslam H Anis
Journal:  Harm Reduct J       Date:  2013-12-10

10.  Predictors of Inpatient Treatment Completion among Females with Opioid Use Disorder: Findings from a Tertiary Care Drug Dependence Treatment Centre of India.

Authors:  Prabhoo Dayal; Siddharth Sarkar; Yatan Pal Singh Balhara
Journal:  Indian J Psychol Med       Date:  2017 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.